CONGRESS GUIDE
ExportFinalProgram_26082016041327
ExportFinalProgram_26082016041327
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ERS International Congress 2016<br />
DETAILED PROGRAMME<br />
SUNDAY 04 SEPTEMBER, 2016<br />
PA987<br />
PA988<br />
PA989<br />
PA990<br />
PA991<br />
PA992<br />
PA993<br />
PA994<br />
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus<br />
salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study<br />
Francesco Patalano (Basel, Switzerland), Francesco Patalano, Jadwiga A. Wedzicha, Jørgen Vestbo, Angel FowlerTaylor,<br />
Tim Ayers, Chau Thach, Neha Ruparelia, Robert Fogel, Donald Banerji<br />
Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus openlabel<br />
tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies<br />
Antonio R. Anzueto (San Antonio, United States of America), Antonio R. Anzueto, Konstantinos Kostikas, Karen Mezzi,<br />
Sebastian Fucile, Giovanni Bader, Steven Shen, Donald Banerji, Robert Fogel<br />
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily<br />
salmeterol/fluticasone (SFC) in COPD patients with 1 exacerbation in the previous year: The FLAME study<br />
Wisia Wedzicha (London, United Kingdom), Jadwiga Wedzicha, Claus F. Vogelmeier, Tim Ayers, Angel FowlerTaylor,<br />
Chau Thach, Petter Olsson, Robert Fogel, Francesco Patalano, Donald Banerji<br />
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily<br />
salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study<br />
Robert Fogel (East Hanover, United States of America), Robert Fogel, Kenneth R. Chapman, Claus F. Vogelmeier, Angel<br />
FowlerTaylor, Tim Ayers, Chau Thach, Sarah Whelan, Karyn Clerkin, Francesco Patalano, Donald Banerji<br />
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in<br />
various sub-groups from the FLAME study<br />
Wisia Wedzicha (London, United Kingdom), Jadwiga Wedzicha, Kenneth Chapman, Angel FowlerTaylor, Tim Ayers, Chau<br />
Thach, Petter Olsson, Robert Fogel, Francesco Patalano, Donald Banerji<br />
Benefits of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) MDI FDC, delivered using a novel MDI cosuspension<br />
technology (GFF MDI), increase with baseline symptom severity in COPD patients (pts)<br />
Fernando J. Martinez (New York, United States of America), Fernando J. Martinez, Leonardo M. Fabbri, Gary T. Ferguson,<br />
Shahid Siddiqui, Chad Orevillo, Patrick Darken, Colin Reisner<br />
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A populationbased<br />
study<br />
Samy Suissa (Montréal, QC, Canada), Samy Suissa, Sophie Dell’Aniello, Pierre Ernst<br />
Pooled analysis of 24-h lung function following treatment with the LAMA/LABA glycopyrronium/formoterol<br />
fumarate fixed-dose combination, delivered by a novel MDI co-suspension technology (GFF MDI), in COPD patients<br />
(pts)<br />
Colin Reisner (Morristown, United States of America), Colin Reisner, Gregory Gottschlich, Faisal Fakih, Andras Koser,<br />
James Krainson, Luis Delacruz, Samir Arora, Gregory Feldman, Krishna Pudi, Shahid Siddiqui, Chad Orevillo, Andrea<br />
Maes<br />
PA995<br />
LATE-BREAKING ABSTRACT: TRILOGY: a phase III study to evaluate the efficacy and safety of an extrafine<br />
triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide<br />
(GB) pMDI (CHF5993) in COPD patients<br />
Géraldine Cohuet (Courbevoie, France), Dave Singh, Alberto Papi, Massimo Corradi, Isabella Montagna, Catherine<br />
Francisco, Géraldine Cohuet, Stefano Vezzoli, Annamaria Muraro, Stefano Petruzzelli, Mario Scuri, Jorgen Vestbo<br />
T-20 Session 184 12:50 - 14:40<br />
Thematic Poster: Systemic biomarkers<br />
Chairs : Konstantinos Kostikas (Basel, Switzerland), Anneke ten Brinke (Molenend, Netherlands), Alain Van Muylem (BRUXELLES,<br />
Belgium), Evangelia Fouka (Thessaloniki, Greece)<br />
PA996<br />
L-arginine pathway metabolites can predict exacerbation independently from beta blocker treatment in patients with<br />
COPD: A follow-up study<br />
Tihamér Szabolcs Molnár (Pécs, Hungary), Tihamer Molnar, Veronika Sarosi, Balazs Illes, Ildiko Horvath, Istvan Ruzsics<br />
PA997<br />
PA998<br />
PA999<br />
Association of the neutrophil-to-lymphocyte ratio with lung function and exacerbations in patients with chronic<br />
obstructive pulmonary disease<br />
Soo-Jung Um (Busan, Republic of Korea), Soo-Jung Um, Seul Lee, Bo Hyoung Kang, Choonhee Son, Kwang Ha Yoo, Ki-<br />
Suck Jung<br />
Role of differential scanning calorimetry (DSC) in the staging of COPD: A new approach to an old definition<br />
problem<br />
Zsuzsanna Szalai (Mosonmagyaróvár, Hungary), Zsuzsanna Szalai, Tamas F. Molnar, Denes Lorinczy<br />
Reactive oxygen metabolite levels are surrogate biomarkers for predicting exacerbation of bronchial asthma<br />
Keitaro Nakamoto (Tokyo, Japan), Keitaro Nakamoto, Masato Watanabe, Mitsuru Sada, Toshiya Inui, Yukari Ogawa,<br />
Masuo Nakamura, Kojiro Honda, Takashi Koide, Saori Takata, Takuma Yokoyama, Takeshi Saraya, Daisuke Kurai, Hiroo<br />
Wada, Haruyuki Ishii, Hajime Takizawa<br />
73 26.08.2016
Change language